1. Home
  2. ADSE vs IVA Comparison

ADSE vs IVA Comparison

Compare ADSE & IVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ADS-TEC ENERGY PLC

ADSE

ADS-TEC ENERGY PLC

HOLD

Current Price

$11.40

Market Cap

858.0M

ML Signal

HOLD

Logo Inventiva S.A. American Depository Shares

IVA

Inventiva S.A. American Depository Shares

HOLD

Current Price

$3.58

Market Cap

883.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADSE
IVA
Founded
1980
2011
Country
Ireland
France
Employees
302
77
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
858.0M
883.8M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
ADSE
IVA
Price
$11.40
$3.58
Analyst Decision
Strong Buy
Analyst Count
0
10
Target Price
N/A
$16.20
AVG Volume (30 Days)
2.5K
659.9K
Earning Date
05-01-2026
03-30-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$549.86
N/A
Revenue Next Year
N/A
$751.20
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.89
$2.94
52 Week High
$13.90
$7.98

Technical Indicators

Market Signals
Indicator
ADSE
IVA
Relative Strength Index (RSI) 48.85 29.34
Support Level $11.20 N/A
Resistance Level $12.01 $4.67
Average True Range (ATR) 0.40 0.28
MACD 0.00 -0.04
Stochastic Oscillator 62.28 5.78

Price Performance

Historical Comparison
ADSE
IVA

About ADSE ADS-TEC ENERGY PLC

ADS-TEC Energy PLC produces, develops, and markets battery-buffered EV charging systems infrastructure, battery storage systems, and cloud-based services that enable the customer to control and manage the system. The company generates revenue mainly through the sale of its products, services, and Big-LinX. Geographically, it derives a majority of its revenue from Germany.

About IVA Inventiva S.A. American Depository Shares

Inventiva SA is a France-based clinical-stage biopharmaceutical company focused on the development of oral small-molecule therapies for the treatment of MASH. The wholly-owned research and development facility and a team with expertise and experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging the expertise, the company is also advancing lanifibranor for the treatment of MASH and has a pipeline of earlier-stage therapeutic programs in oncology. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France.

Share on Social Networks: